Literature DB >> 17828812

Interaction of hepatitis C virus with the type I interferon system.

Friedemann Weber1.   

Abstract

Hepatitis C virus (HCV) needs to tightly manipulate host defences in order to establish infection. The innate immune response slows down viral replication by activating cytokines such as the type I interferons (IFN-alpha/beta), which trigger the synthesis of antiviral proteins and modulate the adaptive immune system. HCV has therefore developed a number of countermeasures to stay ahead of the IFN system. Here, I will attempt to summarize the current state of research regarding IFN responses against HCV and the viral escape strategies. Particular emphasis will be put on the newly discovered mechanisms HCV employs to avoid the induction of IFN in infected cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17828812      PMCID: PMC4611759          DOI: 10.3748/wjg.v13.i36.4818

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  100 in total

1.  VISA is an adapter protein required for virus-triggered IFN-beta signaling.

Authors:  Liang-Guo Xu; Yan-Yi Wang; Ke-Jun Han; Lian-Yun Li; Zhonghe Zhai; Hong-Bing Shu
Journal:  Mol Cell       Date:  2005-09-16       Impact factor: 17.970

2.  Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon.

Authors:  Adrien Breiman; Nathalie Grandvaux; Rongtuan Lin; Catherine Ottone; Shizuo Akira; Mitsutoshi Yoneyama; Takashi Fujita; John Hiscott; Eliane F Meurs
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  Activation of anti-hepatitis C virus responses via Toll-like receptor 7.

Authors:  Jongdae Lee; Christina C N Wu; Ki Jeong Lee; Tsung-Hsien Chuang; Kyoko Katakura; Yu-Tsueng Liu; Michael Chan; Rommel Tawatao; Michelle Chung; Carol Shen; Howard B Cottam; Michael M C Lai; Eyal Raz; Dennis A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-30       Impact factor: 11.205

Review 4.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

5.  Mechanism of the interferon alpha response against hepatitis C virus replicons.

Authors:  Ju-Tao Guo; Ji A Sohn; Qing Zhu; Christoph Seeger
Journal:  Virology       Date:  2004-07-20       Impact factor: 3.616

6.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

Review 7.  The nature of interferon-alpha resistance in hepatitis C virus infection.

Authors:  Jean-Michel Pawlotsky
Journal:  Curr Opin Infect Dis       Date:  2003-12       Impact factor: 4.915

8.  Cytosolic 5'-triphosphate ended viral leader transcript of measles virus as activator of the RIG I-mediated interferon response.

Authors:  Sébastien Plumet; Florence Herschke; Jean-Marie Bourhis; Hélène Valentin; Sonia Longhi; Denis Gerlier
Journal:  PLoS One       Date:  2007-03-14       Impact factor: 3.240

9.  Nonstructural protein 5A does not contribute to the resistance of hepatitis C virus replication to interferon alpha in cell culture.

Authors:  Marc Aus dem Siepen; Volker Lohmann; Manfred Wiese; Stefan Ross; Michael Roggendorf; Sergei Viazov
Journal:  Virology       Date:  2005-06-05       Impact factor: 3.616

10.  Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase.

Authors:  Y L Yang; L F Reis; J Pavlovic; A Aguzzi; R Schäfer; A Kumar; B R Williams; M Aguet; C Weissmann
Journal:  EMBO J       Date:  1995-12-15       Impact factor: 11.598

View more
  8 in total

1.  Aberrant transcription and post-transcriptional processing of hepatitis C virus non-structural genes in transgenic mice.

Authors:  Mayura M Desai; Batbayar Tumurbataar; Yueqing Zhang; Lee-Nien Lillian Chan; Jiaren Sun; Teh-Sheng Chan
Journal:  Transgenic Res       Date:  2011-02-24       Impact factor: 2.788

2.  Specific activation of 2'-5'oligoadenylate synthetase gene promoter by hepatitis C virus-core protein: a potential for developing hepatitis C virus targeting gene therapy.

Authors:  Ying Wang; Shan-Shan Mao; Qiong-Qiong He; Yuan Zi; Ji-Fang Wen; De-Yun Feng
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

3.  Characterization of HCV interactions with Toll-like receptors and RIG-I in liver cells.

Authors:  Erika A Eksioglu; Haizhen Zhu; Lilly Bayouth; Jennifer Bess; Hong-Yan Liu; David R Nelson; Chen Liu
Journal:  PLoS One       Date:  2011-06-17       Impact factor: 3.240

4.  LRRFIP1 Inhibits Hepatitis C Virus Replication by Inducing Type I Interferon in Hepatocytes.

Authors:  Yuan Liu; Ziying Zou; Bing Zhu; Zonghai Hu; Ping Zeng; Lijuan Wu
Journal:  Hepat Mon       Date:  2015-05-23       Impact factor: 0.660

5.  IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma.

Authors:  Martin Probst; Christoph Hoeller; Peter Ferenci; Albert F Staettermayer; Sandra Beinhardt; Hubert Pehamberger; Harald Kittler; Katharina Grabmeier-Pfistershammer
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

6.  Regulation of interferon signaling and HCV‑RNA replication by extracellular matrix.

Authors:  Takuya Kuwashiro; Shinji Iwane; Xia Jinghe; Sachiko Matsuhashi; Yuichiro Eguchi; Keizo Anzai; Kazuma Fujimoto; Toshihiko Mizuta; Naoya Sakamoto; Masanori Ikeda; Nobuyuki Kato; Iwata Ozaki
Journal:  Int J Mol Med       Date:  2018-05-18       Impact factor: 4.101

Review 7.  Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms.

Authors:  Amy D Proal; Michael B VanElzakker
Journal:  Front Microbiol       Date:  2021-06-23       Impact factor: 5.640

8.  HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1.

Authors:  Yanni Chen; Junbo Chen; Hui Wang; Jingjing Shi; Kailang Wu; Shi Liu; Yingle Liu; Jianguo Wu
Journal:  PLoS Pathog       Date:  2013-04-25       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.